Identification Sixteen Metabolic Genes as Potential Biomarkers for Colon
Adenocarcinoma
Abstract
Purpose Colon adenocarcinoma is the most common primary malignant tumor
of the digestive tract. It is still important to find important markers
that affect the prognosis of COAD. This research aims to identify some
key prognosis-related metabolic genes (PRMG) and establish a clinical
prognosis model for COAD patients. Method We used The Cancer Genome
Atlas (TCGA) and Gene Expression Omnibus (GEO) to obtain gene expression
profiles of COAD, and then identified differentially expressed
prognostic-related metabolic genes through R language and Perl software,
Through univariate Cox analysis and least absolute shrinkage and
selection operator (LASSO) Cox analysis to obtain target genes,
established metabolic genes prognostic models and risk scores. Through
COX regression analysis, independent risk factors affecting the
prognosis of COAD were analyzed, and Receiver Operating Characteristic
(ROC) curve analysis of independent prognostic factors was performed and
a nomogram for predicting overall survival was constructed. Perform the
consistency index (C-index) test and decision curve analysis (DCA) on
the nomogram, and use Gene Set Enrichment Analysis (GSEA) to identify
the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of model
genes. Result We selected PRMG based on the expression of metabolic
genes, and used LASSO Cox regression to construct 16 metabolic gene
(SEPHS1, P4HA1, ENPP2, PTGDS, GPX3, CP, ASPA, POLR3A, PKM, POLR2D , XDH,
EPHX2, ADH1B, HMGCL, GPD1L and MAOA) models. The risk score generated
from our model can well predict the survival prognosis of COAD. A
nomogram based on the clinicopathological characteristics and risk
scores of COAD can personally predict the overall survival rate of COAD
patients. Conclusion We comprehensively identified metabolic genes
related to the prognosis of COAD. The risk score based on the expression
of 16 metabolic genes can effectively predict the prognosis of patients
with COAD.